GAS CHROMATOGRAPHIC DETERMINATION OF SODIUM VALPROATE IN NANOPARTICLE-BASED PREPARATIONS

Download full text PDF
DOI: https://doi.org/None
Issue: 
5
Year: 
2016

D.A. Kardonsky, A.A. Eganov, E.V. Moskaleva I.M. Sechenov First Moscow State Medical University; 8, Trubetskaya St., Build. 2, Moscow 119991, Russian Federation

Introduction. Valproic acid (VPA) is a broad-spectrum anticonvulsant having a high toxicity. The design of its novel formulation – nanoparticles (NPs) that preserve anticonvulsant function and reduce the total concentration of VPA in the body is promising. Objective. To develop a procedure for the gas chromatographic determination of sodium valproate as its ready-made formulations based on polybutylcyanoacrylate nanoparticles. Material and methods. Sodium valproate as ready-made formulations based on polybutylcyanoacrylate nanoparticles was analyzed by gas chromatography with a flame ionization detector after derivation with a mixture of pentafluoropronionic anhydrate and 2,2,3,3,3-pentafluoro-1-propanol. The levels of sodium valproate were quantified using the method of the internal standard that was 3-n-pentylphosphate (TPP). Results. A gas chromatographic procedure was developed to determine the levels of sodium valproate in the preparations based on polybutylcyanoacrylate nanoparticles. The procedure was validated using the following characteristics: specificity, linearity, accuracy, precision, and quantitation limit. Conclusion. The developed and validated gas chromatographic assay is rapid and reliable in determining the level of sodium valproate in its ready-made formulations.
Keywords: 
gas chromatography
sodium valproate
polybutylcyanoacrylate nanoparticles
References: 
  1. Shallcross R., Bromley R.L., Cheyne C.P., Garcia-Finana M. Irwin B., Morrow J., Baker G.A.; for the Liverpool and Manchester Neurodevelopment Group; UK Epilepsy and Pregnancy Register. In utero exposure to levetiracetamvs valproate: development and language at 3 years of age. Neurology, 2014; 82: 213–21.
  2. Shen D.D., Ojemann G.A., Rapport R.L., Dills R.L., Friel P.N., Levy R.H. Low and variable presence of valproic acid in human brain. Neurology, 1992; 42 (3 Pt 1): 582–5.
  3. Epigenetic Mechanisms in Autism Spectrum DisorderAdrianZhub et al, International Review of Neurobiology, Vol. 115; 2014.
  4. Kovalenko A.E., Kardonskiy D.A., Eganov A.A., Grishin D.A. Sovremennye podhody k analizu narkoticheskih veshhestv v biologicheskih ob``ektah. Sudebno-medicinskaya e`kspertiza, 2007; 50 (2): 28. [Kovalenko A.E., Kardonsky D.A., Eganov A.A., Grishin D.A. Modern approaches to the analysis of drugs in biological objects. Sudebno – meditsinskaia ekspertiza, 2007; 50 (2): 28 (in Russian)].
  5. Guidance for Industry: Bioanalytical method validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evolution and Research (CDER). U.S. Government Printing Offce: Washington, DC, 2001.
  6. Guideline on validation of bioanalytical methods (draft). European Medicines Agency. Committee for medicinal products for human use: London, 2009